A resident in the Houston JLab. Corinnova is a medical device firm developing EpicHeart, a soft robotic non-blood contacting biventricular cardiac assist device to treat end-stage heart failure (HF). EpicHeart is designed to eliminate 40% of the adverse events associated with existing cardiac assist technologies, and may expand eligible patients by 3 to 4 times. The device may reverse the progression of HF: a blockbuster application that - in part supported by a major Wellcome Trust investment -- was tested in a large animal HF model during 2018. The device deploys minimally invasively into the pericardial sac in under 30 seconds, and has shown the ability to increase cardiac output by up to 50% in large animal studies. In the Fall 2017, the firm received notice of allowance of a seminal patent to protect its intellectual property associated with the worldâs first minimally invasively-delivered soft robotic heart device to support heart function and that the Company had been accepted to become a resident at Johnson & Johnson Innovation, JLABS @ TM
